

Name: _____

HCN: _____

Date of Birth: _____



CC6210 0431 12 2023

Weight: _____ kg Height: _____ cm Body Surface Area (BSA) = _____

Allergies:

No Known

Date: DD/MONTH/YYYY

Planned Administration Date: DD/MONTH/YYYY

Cycle _____ of _____

Cycle Duration: **28 days**

Date of previous cycle: DD/MONTH/YYYY

MAY PROCEED WITH DOSES AS WRITTEN IF:

- ANC **greater than or equal to** $1.5 \times 10^9/L$ and platelets **greater than or equal to** $100 \times 10^9/L$, otherwise notify Medical Oncologist.
- LFTs and Bilirubin assessed.
- Creatinine clearance assessed.

PREMEDICATIONS (FOR COMMUNITY PHARMACY):

30 minutes prior to temozolomide: ondansetron 8 mg PO daily on days 1 to 5

Other: _____

CHEMOTHERAPY (FOR COMMUNITY PHARMACY):

Cycle 1

temozolomide 150 mg/m² X BSA = _____ mg PO daily on days 1 to 5

Dose modification: temozolomide 100 mg/m² X BSA = _____ mg PO daily on days 1 to 5

This prescription is NOT eligible for pharmacist prescribing by dispensing pharmacist.

Cycles 2+

temozolomide 200 mg/m² X BSA = _____ mg PO daily on days 1 to 5

Dose modification: temozolomide 150 mg/m² X BSA = _____ mg PO daily on days 1 to 5

Dose modification: temozolomide 100 mg/m² X BSA = _____ mg PO daily on days 1 to 5

This prescription is NOT eligible for pharmacist prescribing by dispensing pharmacist.

PLEASE REFER TO CHEMOTHERAPY LETTER WHEN ORDERING SUPPORTIVE MEDICATIONS FOR THIS PATIENT

Authorized Prescriber: _____ Date: DD/MONTH/YYYY Time: _____

Authorized Prescriber's Signature: _____ ID #: _____

Nurse's Name: _____ Date: DD/MONTH/YYYY Time: _____

Nurse's Signature: _____

THIS IS A CONTROLLED DOCUMENT. PLEASE ENSURE THAT YOU ARE READING THE MOST RECENT VERSION.